Back to search

213 result(s):

CHANGES IN BODY MASS INDEX BEFORE AND AFTER STARTING DOLUTEGRAVIR AND COMPARED TO PROTEASE INHIBITORS IN CHILDREN AND ADOLESCENTS LIVING WITH HIV IN EUROPE AND THAILAND

PRE-CLINICAL PROFILES OF HIV-1 CAPSID INHIBITORS VH4004280 (VH-280) AND VH4011499 (VH-499)

EFFECTIVENESS AND DURABILITY OF DOLUTEGRAVIR/LAMIVUDINE IN OLDER PEOPLE WITH HIV FROM THE VETERANS AGING COHORT STUDY (VACS)

PERSPECTIVES OF PEOPLE WITH HIV (PWH) 12 MONTHS FOLLOWING A SWITCH TO CABOTEGRAVIR▼ AND RILPIVIRINE▼ LONG-ACTING (CAB+RPV LA) IN AN OBSERVATIONAL REAL-WORLD US STUDY (BEYOND)

INFLUENCERS AND DECISION-MAKING FACTORS FOR CHOOSING INJECTABLE PREP AMONG MEN WHO HAVE SEX WITH MEN AND TRANSGENDER MEN IN THE UNITED STATES

Can’t find what you’re looking for or would like to discuss our data in person? Contact your MSL

Contact us

NP-GBL-HVX-WCNT-220014 September 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.